<DOC>
	<DOCNO>NCT02638103</DOCNO>
	<brief_summary>A study evaluate long-term safety , tolerability , efficacy subcutaneous administration TEV-48125 adult patient chronic migraine episodic migraine</brief_summary>
	<brief_title>Efficacy Safety Subcutaneous Administration TEV-48125 Preventive Treatment Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients Rolling Over Pivotal Efficacy Studies may include study meet follow criterion : Patient sign date inform consent document . Patient must complete pivotal efficacy study without major protocol violation . Additional criterion apply , please contact investigator information Patients Not Rolling Over Pivotal Efficacy Studies may include study meet follow criterion : Males female age 18 70 year , inclusive , migraine onset ≤50 year age Patient sign date inform consent document . Patient history migraine clinical judgment suggest migraine diagnosis Patient fulfill criterion episodic migraine ( EM ) chronic migraine ( CM ) Total body weight 99 265 lbs. , inclusive All patient must nonchildbearing potential Patients must simultaneously use 2 form highly effective contraception method Patients remain abstinent throughout study Patients sexual preference precludes possibility pregnancy . Female patient childbearing potential must negative serum betahuman chorionic gonadotropin ( βHCG ) pregnancy test prior randomization ( confirm urine dipstick baseline ) . The patient must willing able comply study restriction , remain clinic require duration study period , return clinic followup evaluation specify protocol . Additional criterion apply , please contact investigator information Patients Rolling Over Pivotal Efficacy Studies exclude participate study meet follow criterion : Pregnant nursing female Compliance daily diary entry lower 75 % last month doubleblind treatment period pivotal efficacy study Patients Not Rolling Over Pivotal Efficacy Studies exclude participate study meet follow criterion : Clinically significant finding discretion investigator Evidence medical history clinically significant psychiatric issue , include suicide attempt past , suicidal ideation specific plan past 2 year History clinically significant cardiovascular disease vascular ischemia Known infection history human immunodeficiency virus , tuberculosis , chronic hepatitis B C infection Past current history cancer past 5 year , except appropriately treat nonmelanoma skin carcinoma Pregnant nursing female History hypersensitivity reaction inject protein , include monoclonal antibody h. Participation clinical study new chemical entity prescription medicine within 2 month study drug administration 5 halflives , whichever longer Any finding consider clinically significant judgment investigator History alcohol drug abuse past 2 year , alcohol drug dependence past 5 year The patient participate successfully complete study , opinion healthcare provider investigator , follow reason : mentally legally incapacitate unable give consent reason custody due administrative legal decision , tutelage , admit sanitarium social institution unable contacted case emergency condition , , opinion investigator , make patient inappropriate inclusion study Patient study center sponsor employee directly involve study relative employee . Additional criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>